| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Vedolizumab and Anti-Vedolizumab Antibody, DOSEASSURE VDZ
Test CodeLAB01224
Alias/See Also
LAB01224
LabCorp TC: 504567
Anti-integrin drug
Entyvio
LabCorp TC: 504567
Anti-integrin drug
Entyvio
CPT Codes
80280, 82397
Includes
Vedolizumab Drug Level
Anti-Vedolizumab Antibody
Anti-Vedolizumab Antibody
Preferred Specimen
3 mL Serum
(Marble, Gold, Red)
(Marble, Gold, Red)
Minimum Volume
1 mL
Instructions
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection.
Send serum/plasma in plastic transport tube.To avoid delays in turnaround time when requesting multiple test on frozen samples, please submit separate frozen specimens for each test requested.
Send serum/plasma in plastic transport tube.To avoid delays in turnaround time when requesting multiple test on frozen samples, please submit separate frozen specimens for each test requested.
Transport Temperature
Frozen
Specimen Stability
Frozen: 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, gross lipemia
Methodology
Electrochemiluminescence Immunoassay (ECLIA)
Report Available
8-15 days
Limitations
Drug half-life should be taken into consideration when interpreting concentrations measured in non-trough collections.
In the absence of anti-vedolizumab antibodies, the vedolizumab drug level reflects the total vedlizumab concentration. In the presence of anti-vedolizumab antibodies, the vedolizumab concentrations reflects the antibody-unbound of vedolizumab.
The presence of vedolizumab drug, even at concentrations well above the target treatment levels, does not interfere with anti-vedolizumab antibody measurement. All positive anti-vedolizumab antibody results are verifed by a confirmatory test.
In the absence of anti-vedolizumab antibodies, the vedolizumab drug level reflects the total vedlizumab concentration. In the presence of anti-vedolizumab antibodies, the vedolizumab concentrations reflects the antibody-unbound of vedolizumab.
The presence of vedolizumab drug, even at concentrations well above the target treatment levels, does not interfere with anti-vedolizumab antibody measurement. All positive anti-vedolizumab antibody results are verifed by a confirmatory test.
Clinical Significance
Provides serum concentrations of vedolizumab and anti-vedolizumab antibodies in order to optimize treatment and facilitate clinical decision-making.
Performing Laboratory
LabCorp